News headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.1599859669602 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media headlines that may have effected Accern’s analysis:

Spectrum Pharmaceuticals (NASDAQ:SPPI) opened at $18.92 on Monday. Spectrum Pharmaceuticals has a twelve month low of $4.17 and a twelve month high of $21.95. The company has a quick ratio of 4.89, a current ratio of 5.04 and a debt-to-equity ratio of 0.33.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.06). Spectrum Pharmaceuticals had a negative net margin of 58.94% and a negative return on equity of 29.73%. The company had revenue of $36.40 million during the quarter, compared to analyst estimates of $33.27 million. During the same period in the previous year, the firm posted ($0.07) earnings per share. The company’s revenue was up 9.0% compared to the same quarter last year. equities research analysts anticipate that Spectrum Pharmaceuticals will post -1.03 EPS for the current fiscal year.

SPPI has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Spectrum Pharmaceuticals in a report on Wednesday, August 16th. Guggenheim started coverage on Spectrum Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $32.00 price target for the company. Jefferies Group boosted their price target on Spectrum Pharmaceuticals to $25.00 and gave the company a “buy” rating in a report on Friday, October 20th. Zacks Investment Research downgraded Spectrum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Finally, ValuEngine raised Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $21.40.

ILLEGAL ACTIVITY WARNING: “Spectrum Pharmaceuticals (SPPI) Earns Daily News Impact Score of 0.04” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Insider Buying and Selling by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Stock Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.